Atomic AI
AI-driven 3D RNA structure platform (ATOM-1) for RNA drug discovery
Biotech
📍 South San Francisco, CA
Founded 2021
Current Valuation
Private
PRIVATE
Atomic AI is a South San Francisco biotech founded in 2021 by Stanford AI PhD Raphael Townshend that fuses machine learning with structural biology to predict and design RNA structure. It launched publicly in January 2023 with a $35M Series A led by Playground Global (with angels including Nat Friedman and Packy McCormick), and develops ATOM-1, a foundation model for RNA structure/function used to design RNA therapeutics and RNA-targeted small molecules.
Company Profile
HQ
South San Francisco, CA
Growth
Early platform stage; building RNA structure foundation models
Last Round
Series A — $35M (Jan 2023) · Lead: Playground Global
Fundraising Status
Series A · $35M · 3y 6mo ago
privateTotal raised $35M1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series A | $35M | Jan 2023 | Playground Global | — |
Founders & Key People
Raphael Townshend
Investors
Playground Global · Nat Friedman · Not Boring Capital (Packy McCormick)
Products
- ATOM-1 RNA foundation model
- RNA structure & function prediction
- RNA-targeted small molecules and RNA therapeutics design
Competitors
Inceptive · Therna Biosciences
BiotechRNA TherapeuticsMachine LearningTechBioAI Drug Discovery
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.